Risperidone for treatment-resistant schizophrenia

Initial clinical experience in a state hospital

Peter F. Buckley, Karl Donenwirth, Kenneth E. Bayer, Christine Lys, Zafar Ibrahim, S. Charles Schulz

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20% reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2-17%) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
JournalJournal of Pharmacy Technology
Volume12
Issue number6
DOIs
StatePublished - Jan 1 1996

Fingerprint

State Hospitals
Risperidone
Brief Psychiatric Rating Scale
Schizophrenia
Antipsychotic Agents
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Risperidone for treatment-resistant schizophrenia : Initial clinical experience in a state hospital. / Buckley, Peter F.; Donenwirth, Karl; Bayer, Kenneth E.; Lys, Christine; Ibrahim, Zafar; Schulz, S. Charles.

In: Journal of Pharmacy Technology, Vol. 12, No. 6, 01.01.1996, p. 271-275.

Research output: Contribution to journalReview article

Buckley, Peter F. ; Donenwirth, Karl ; Bayer, Kenneth E. ; Lys, Christine ; Ibrahim, Zafar ; Schulz, S. Charles. / Risperidone for treatment-resistant schizophrenia : Initial clinical experience in a state hospital. In: Journal of Pharmacy Technology. 1996 ; Vol. 12, No. 6. pp. 271-275.
@article{968c021a5dec488ab2e69d3a9e2086d2,
title = "Risperidone for treatment-resistant schizophrenia: Initial clinical experience in a state hospital",
abstract = "Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20{\%} reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2-17{\%}) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.",
author = "Buckley, {Peter F.} and Karl Donenwirth and Bayer, {Kenneth E.} and Christine Lys and Zafar Ibrahim and Schulz, {S. Charles}",
year = "1996",
month = "1",
day = "1",
doi = "10.1177/875512259601200608",
language = "English (US)",
volume = "12",
pages = "271--275",
journal = "Journal of Pharmacy Technology",
issn = "8755-1225",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Risperidone for treatment-resistant schizophrenia

T2 - Initial clinical experience in a state hospital

AU - Buckley, Peter F.

AU - Donenwirth, Karl

AU - Bayer, Kenneth E.

AU - Lys, Christine

AU - Ibrahim, Zafar

AU - Schulz, S. Charles

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20% reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2-17%) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.

AB - Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20% reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2-17%) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.

UR - http://www.scopus.com/inward/record.url?scp=0030446358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030446358&partnerID=8YFLogxK

U2 - 10.1177/875512259601200608

DO - 10.1177/875512259601200608

M3 - Review article

VL - 12

SP - 271

EP - 275

JO - Journal of Pharmacy Technology

JF - Journal of Pharmacy Technology

SN - 8755-1225

IS - 6

ER -